Sweet heart - Contributions of metabolism in the development of heart failure in diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue SUPPL. 1, 2008, Pages

  Stratmann, B ^a   Tschoepe, D ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cardiac metabolism; Diabetic cardiomyopathy; Lipotoxicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBOHYDRATE; CD36 ANTIGEN; CREATINE PHOSPHATE; FATTY ACID; GLUCOSE TRANSPORTER 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE B; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CORONARY ARTERY; ENERGY METABOLISM; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GENE ACTIVATION; GENE OVEREXPRESSION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN BINDING; INSULIN RESISTANCE; LIPID METABOLISM; MICROVASCULARIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHOSPHORYLATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; UPREGULATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENERGY METABOLISM; FATTY ACIDS; HEART FAILURE; HUMANS; INSULIN RESISTANCE;

EID: 54549087777     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1081496     Document Type: Review

References (75)

1. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006; 291: H1489-H15O6
2. Atkinson LL, Fischer MA, Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 2002; 277: 29424-29430
3. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-2441
4. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-778
5. Carroll R, Carley AN, Dyck JR, Severson DL. Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts. Am J Physiol Endocrinol Metab 2005; 288: E900-E906
6. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig MW, Sharp TL, Sambandam N, Olson MW, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005; 96: 225-233
7. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001; 107: 813-822
8. Cohen P. The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. Philos Trans R Soc Lond B Biol Sci 1999; 354: 485-495
9. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991; 338: 973-976
10. Coort SL, Hasselbaink DM, Koonen DP, Willems J, Coumans WA, Chabowski A, Vusse GJ van der, Bonen A, Glatz JF, Luiken JJ. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes 2004; 53: 1655-1663
11. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789
12. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardioi 2002; 40: 271-277
13. Finck BN, Han Y, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 2003; 100: 1226-1231
14. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002; 109: 121-130
15. Fulton D, Gratton JP, MacCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601
16. Giles TD, Sander GE. Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations. Cardiol Clin 2004; 22: 553-568
17. Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, Arsdall M Van, Adrogue JV, Brown KK, Taegtmeyer H. Activation of PPAR-gamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 2005; 289: E328-E336
18. Guimbal C, Kilimann MW. A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDMA cloning and functional expression. J Biol Chem 1993; 268: 8418-8421
19. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991; 122: 795-801
20. Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007; 115: 1371-1375
21. Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005; 18: 949-957
22. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006: 440: 944-948
23. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006; 55: 466-473
24. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 2003; 285: H1261-H1269
25. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 1999; 274: 26761-26766
26. Ingwall JS. Is creatine kinase a target for AMP-activated protein kinase in the heart? J Mol Cell Cardiol 2002; 34: 1111-1120
27. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004: 95: 135-145
28. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002; 51: 3020-3024
29. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-2673
30. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51: 597-604
31. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000; 5: 167-173
32. Kannel WB, MacGee DL. Diabetes and cardiovascular disease. The Framingham study. Jama 1979; 241: 2035-2038
33. King KT, Okere IC, Sharma N, Dyck JR, Reszko AE, MacElfresh TA, Kerner J, Chandler MP, Lopaschuk GD, Stanley WC. Regulation of cardiac malonyl-CoA content fatty acid oxidation during increased cardiac power. Am J Physiol Heart Circ Physiol 2005; 289: H1033-H1037
34. Koonen DP, Glatz JF, Bonen A, Luiken JJ. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta 2005; 1736: 163-180
35. Lamb HJ, Beyerbacht HP, Laarse A van der, Stoel BC, Doombos J, Wall EE van der, Roos A de. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999; 99: 2261-2267
36. Lautamaki R, Airaksinen KE, Seppanen M, Toikka J, Harkonen R, Luotolahti M, Borra R, Sundell J, Knuuti J, Nuutila P. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease. Diabetes 2006; 55: 511-516
37. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999; 96: 7473-7478
38. Luiken JJ, Coort SL, Koonen DP, Bonen A, Glatz JF. Signalling components involved in contraction-inducible substrate uptake into cardiac myocytes. Proc Nutr Soc 2004; 63: 251-258
39. Luiken JJ, Coort SL, Koonen DP, Horst DJ van der, Bonen A, Zorzano A, Giatz JF. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch 2004; 448: 1-15
40. Monti LD, Landoni C, Setola E, Galluccio E, Lucotti P, Sandoli EP, Origgi A, Lucignani G, Piatti P, Fazio F. Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients. Am J Physiol Heart Circ Physiol 2004; 287: H1225-H1231
41. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004; 364: 1786-1788
42. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007; 356: 1140-1151
43. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Huhn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-2196
44. Neubauer S, Horn M, Pabst T, Godde M, Lubke D, Jilling B, Hahn D, Ertl G. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 1995; 16 (Suppl 0): 115-118
45. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992; 86: 1810-1818
46. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93: 1905-1912
47. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899-904
48. Opie LH. Effect of fatty acids on contractility and rhythm of the heart. Nature 1970; 227: 1055-1056
49. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002; 106: 606-612
50. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxta-membrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997; 272: 29911-29918
51. Peterson LR, Herrero P, Schechtman XB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109: 2191-2196
52. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 2001; 104: 2923-2931
53. Rosen P, Du X, Tschope D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol? Mol Cell Biochem 1998; 188: 103-111
54. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 2001; 107: 181-189
55. Schupp M, Kintscher U, Fielitz J, Thomas J, Pregla R, Hetzer R, Unger T, Regitz-Zagrosek V. Cardiac PPARalpha expression in patients with dilated cardiomyopathy. Eur J Heart Fail 2006; 8: 290-294
56. Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy. Rev Cardiovasc Med 2003; 4 (Suppl 6): S50-S57
57. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. Faseb J 2004; 18: 1692-1700
58. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000; 5: 415-418
59. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005; 112: 3577-3583
60. Stanley WC, Lopaschuk GD, MacCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997; 34: 25-33
61. Stratton IM, Adler AI, Neil HA Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj 2000; 321: 405-412
62. Susic D, Varagic J, Ahn J, Frohlich ED. Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 2004; 19: 336-340
63. Taegtmeyer H. Switching metabolic genes to build a better heart. Circulation 2002; 106: 2043-2045
64. Taegtmeyer H, MacNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 2002; 105: 1727-1733
65. Taegtmeyer H, Passmore JM. Defective energy metabolism of the heart in diabetes. Lancet 1985; 1: 139-141
66. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96
67. Teusink B, Voshol PJ, Dahlmans VE, Rensen PC, Pijl H, Romijn JA, Havekes LM. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 2003; 52: 614-620
68. Ungar I, Gilbert M, Siegel A, Blain JM, Bing RJ. Studies on myocardial metabolism. IV. Myocardial metabolism in diabetes. Am J Med 1955; 18: 385-396
69. Heerebeek L van, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, Velden J van der, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117: 43-51
70. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 2003; 3: 279-288
71. Wyss M, Wallimann T. Creatine metabolism and the consequences of creatine depletion in muscle. Mol Cell Biochem 1994; 133-134: 51-66
72. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003; 111: 419-426
73. Young ME, MacNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002: 105: 1861-1870
74. Yuan M, Konstantopoulas N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-1677
75. Zhou YT, Grayburn P, Karim A Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000: 97: 1784-1789